Diagnostic and Prognostic Values of Plasma Levels of Fibrinolytic Markers in Ovarian Cancer

Ho, Chao‐Hung; Yuan, Chiou‐Chung; Liu, Shian-Min

doi:10.1006/gyno.1999.5610

Cited by 30 publications

(14 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…32 It is a sensitive marker of the fibrinolytic enhancement. 32 As in many other human malignancies, [33][34][35][36][37][38] including lung carcinoma, DD might have prognostic significance. 12,15,39 In 1993, Seitz et al 12 reported that TAT and DD were significantly increased in patients with metastatic disease and that elevated TAT values at diagnosis might be prognostically significant.…”

Section: Discussionmentioning

confidence: 99%

Plasma levels of D‐dimer in lung carcinoma

Buccheri

Torchio

Ferrigno

2003

Cancer

View full text Add to dashboard Cite

BACKGROUNDThe activation of the clotting‐fibrinolytic system in cancer patients is common and represents an unfavorable clinical sign. D‐dimer (DD) is a sensitive marker of fibrinolysis.METHODSThe current study comprised 826 new lung carcinoma patients seen consecutively in a single institution over a 10‐year period (1992–2001). For each patient, 31 variables, including DD and survival duration, were available for analysis.RESULTSOnly weak relationships between DD and the other variables were found. The DD variable correlated best with the level of lactate dehydrogenase, performance status, tissue polypeptide antigen, stage of disease, and the number of metastases (rho = 0.33, −0.25, 0.18, 0.18, and 0.15, respectively). The D‐dimer distinguished patients with different prognoses. The median survival periods were 154 days (95% confidence interval [CI], 122–189 days) and 308 days (95% CI, 227–409 days; log rank statistic, 26.56; P < 0.01), respectively, for abnormally elevated and normal values. The difference was greater in patients with adenocarcinoma and in patients presenting with a less advanced disease, especially in patients with pathologic Stage Ia disease. The best multivariate survival model selected 10 significant covariates, including DD.CONCLUSIONSThe authors recommend measuring the plasma level of DD in all new lung carcinoma patients. This measurement may help to formulate individual prognoses and can be used to indicate adjuvant treatment for surgical patients. Cancer 2003;97:3044–52. © 2003 American Cancer Society.DOI 10.1002/cncr.11432

show abstract

Section: Discussionmentioning

confidence: 99%

Plasma levels of D‐dimer in lung carcinoma

Buccheri

Torchio

Ferrigno

2003

Cancer

View full text Add to dashboard Cite

show abstract

“…11 Most of these proteases do not reach generally detectable levels in the circulation until late-stage disease, presumably as a result of increased tumor bulk. 22 Therefore, it is unlikely that relying on measuring these proteins will be useful in the diagnosis of early stage cancer, when there is the best chance of survival. Because host response proteins exist at substantially higher concentrations than the enzymes that process them within the tumor microenvironment, measurement of the modified forms of these analytes is more likely to serve that purpose.…”

Section: Discussionmentioning

confidence: 99%

Classification of cancer types by measuring variants of host response proteins using SELDI serum assays

Fung¹,

Yip²,

Lomas³

et al. 2005

Intl Journal of Cancer

168

160

View full text Add to dashboard Cite

Protein expression profiling has been increasingly used to discover and characterize biomarkers that can be used for diagnostic, prognostic or therapeutic purposes. Most proteomic studies published to date have identified relatively abundant host response proteins as candidate biomarkers, which are often dismissed because of an apparent lack of specificity. We demonstrate that 2 host response proteins previously identified as candidate markers for early stage ovarian cancer, transthyretin and inter-alpha trypsin inhibitor heavy chain 4 (ITIH4), are posttranslationally modified. These modifications include proteolytic truncation, cysteinylation and glutathionylation. Assays using Surface Enhanced Laser Desorption/Ionization Time of Flight Mass Spectrometry (SELDI-TOF-MS) may provide a means to confer specificity to these proteins because of their ability to detect and quantitate multiple posttranslationally modified forms of these proteins in a single assay. Quantitative measurements of these modifications using chromatographic and antibody-based ProteinChip1 array assays reveal that these posttranslational modifications occur to different extents in different cancers and that multivariate analysis permits the derivation of algorithms to improve the classification of these cancers. We have termed this process host response protein amplification cascade (HRPAC), since the process of synthesis, posttranslational modification and metabolism of host response proteins amplifies the signal of potentially low-abundant biologically active disease markers such as enzymes. ' 2005 Wiley-Liss, Inc.

show abstract

“…A smaller study of 25 patients with ovarian cancer found no significant correlation between suPAR levels in the plasma and the cancer tissue. 120 In HCC, plasma uPAR was significantly higher in cirrhosis than in stage I of HCC and significantly higher in stage IV than stages I and II of HCC. Leading to the conclusion that plasma uPAR may be used in early diagnosis of HCC.…”

Section: S O L U B L E U P a R L E V E L S I N P L A S M A O F C A mentioning

confidence: 98%

Clinical significance of urokinase‐type plasminogen activator receptor (uPAR) expression in cancer

Bock

Wang

2003

Medicinal Research Reviews

136

103

View full text Add to dashboard Cite

The involvement of the urokinase-type plasminogen activator (uPA) system in particular has been extensively studied in the pathogenesis of cancer. The molecular role of the uPA receptor (uPAR) is well characterized with its participation in cell migration and extracellular matrix (ECM) degradation. Over-expression of uPAR in cancer has been demonstrated in many studies and is considered an attractive target for anticancer agents. We and others have down-regulated uPAR expression in an attempt to inhibit cancer metastasis based on its molecular role. Uniquely, uPAR which is a glycosyl phosphatidylinositol anchored protein is not only bound to the cell surface but also has a soluble form, suPAR. There is now accumulated clinical and experimental evidence supporting the significant role of uPAR and its soluble counterpart in a number of solid cancers. The expression of uPAR can be associated with tumor cells or stromal cells or both. Differences observed in the expression of uPAR using immunohistochemistry (IHC) are likely explained by the use of different antibodies and techniques rather than true cellular differences and are reviewed here. This review summarizes the clinical relevance of uPAR and its soluble form in the prognosis and diagnosis of different cancers.

show abstract

Diagnostic and Prognostic Values of Plasma Levels of Fibrinolytic Markers in Ovarian Cancer

Cited by 30 publications

References 10 publications

Plasma levels of D‐dimer in lung carcinoma

Plasma levels of D‐dimer in lung carcinoma

Classification of cancer types by measuring variants of host response proteins using SELDI serum assays

Clinical significance of urokinase‐type plasminogen activator receptor (uPAR) expression in cancer

Contact Info

Product

Resources

About